Novartis already produces the leading drug in the radiopharmaceutical field. Now, it is devoting even more attention to these cancer treatments with a new acquisition.Â
Novartis is paying $1 billion upfront and up to an additional $750 million if certain milestones are met to acquire startup Mariana Oncology, the latter company announced Thursday. Mariana is a three-year-old company developing medicines that drop radioactive isotopes on cancer cells, decimating them in a more potent way than traditional radiation treatment. The startup was founded by investors Atlas Venture, Access Biotechnology, and RA Capital Management.Â
The acquisition presents a new avenue for Novartis, which already sells the leading radiopharmaceutical drug, Pluvicto. That drug is designed to treat prostate cancer by delivering the radioactive isotope lutetium-177 to a protein found on cancer cells called PSMA. Pluvicto is edging into blockbuster territory just a couple years after its launch; the drug brought in $980 million in sales last year.Â
Click this link for the original source of this article.
Author: Allison DeAngelis
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.